GRCE
Grace Therapeutics·NASDAQ
--
--(--)
--
--(--)
GRCE fundamentals
During Q3 2026, Grace Therapeutics (GRCE) reported revenue of --, a YoY change of 0.00%. Net income was -2.31M, a YoY change of 44.28%. Click to view the full income statement and explore the company's earnings performance.
Income Statement
Q1,2018 | Q2,2018 | Q3,2018 | Q4,2018 | Q1,2019 | Q2,2019 | Q3,2019 | Q4,2019 | Q1,2020 | Q2,2020 | Q3,2020 | Q4,2020 | Q1,2021 | Q2,2021 | Q3,2021 | Q4,2021 | Q1,2022 | Q2,2022 | Q3,2022 | Q4,2022 | Q1,2023 | Q2,2023 | Q3,2023 | Q4,2023 | Q1,2024 | Q2,2024 | Q3,2024 | Q4,2024 | Q1,2025 | Q2,2025 | Q3,2025 | Q4,2025 | Q1,2026 | Q2,2026 | Q3,2026 | TTM |
|---|
Start Date | Apr 1, 2017 | Jul 1, 2017 | Oct 1, 2017 | Jan 1, 2018 | Apr 1, 2018 | Jul 1, 2018 | Oct 1, 2018 | Jan 1, 2019 | Apr 1, 2019 | Jul 1, 2019 | Oct 1, 2019 | Jan 1, 2020 | Apr 1, 2020 | Jul 1, 2020 | Oct 1, 2020 | Jan 1, 2021 | Apr 1, 2021 | Jul 1, 2021 | Oct 1, 2021 | Jan 1, 2022 | Apr 1, 2022 | Jul 1, 2022 | Oct 1, 2022 | Jan 1, 2023 | Apr 1, 2023 | Jul 1, 2023 | Oct 1, 2023 | Jan 1, 2024 | Apr 1, 2024 | Jul 1, 2024 | Oct 1, 2024 | Jan 1, 2025 | Apr 1, 2025 | Jul 1, 2025 | Oct 1, 2025 | -- |
End Date | Jun 30, 2017 | Sep 30, 2017 | Dec 31, 2017 | Mar 31, 2018 | Jun 30, 2018 | Sep 30, 2018 | Dec 31, 2018 | Mar 31, 2019 | Jun 30, 2019 | Sep 30, 2019 | Dec 31, 2019 | Mar 31, 2020 | Jun 30, 2020 | Sep 30, 2020 | Dec 31, 2020 | Mar 31, 2021 | Jun 30, 2021 | Sep 30, 2021 | Dec 31, 2021 | Mar 31, 2022 | Jun 30, 2022 | Sep 30, 2022 | Dec 31, 2022 | Mar 31, 2023 | Jun 30, 2023 | Sep 30, 2023 | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | -- |
Fiscal Year-End | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | -- |
Revenue | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | 81.00K -- | 115.00K -- | -- -- | -- -- | -- -- | 0 -100.00% | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Sales and Services Revenue | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | 81.00K -- | 115.00K -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Cost of Revenue | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | 36.00K -- | 40.00K -- | -- -- | -- -- | -- -- | 0 -100.00% | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Cost of Goods and Services | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 76.00K -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Gross Profit | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | 45.00K -- | 75.00K -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Operating Expenses | 2.16M -- | 3.51M -- | 4.11M -- | 5.71M -- | 7.55M +250.26% | 8.08M +130.43% | 7.85M +90.78% | 10.44M +82.76% | 8.01M +6.02% | 6.25M -22.56% | 6.15M -21.70% | 4.03M -61.38% | 4.12M -48.53% | 8.03M +28.44% | 2.01M -67.31% | 2.38M -41.08% | 3.15M -23.68% | 3.57M -55.60% | 4.47M +122.70% | 4.40M +85.39% | 4.73M +50.40% | 5.11M +43.20% | 4.25M -5.12% | 38.07M +764.71% | 4.45M -5.84% | 2.09M -59.04% | 3.04M -28.32% | 3.26M -91.43% | 4.96M +11.43% | 4.83M +130.93% | 3.70M +21.72% | 3.18M -2.45% | 3.09M -37.74% | 2.53M -47.65% | 2.45M -33.88% | 11.25M -- |
Selling, General and Administrative Expenses | 629.33K -- | 828.20K -- | 691.06K -- | 1.02M -- | 788.43K +25.28% | 1.01M +22.41% | 845.79K +22.39% | 2.36M +132.12% | 1.82M +130.33% | 2.30M +126.97% | 2.23M +164.13% | 2.11M -10.35% | 2.37M +30.23% | 1.46M -36.64% | 1.33M -40.42% | 1.51M -28.58% | 2.68M +13.15% | 2.98M +104.53% | 2.05M +53.72% | 2.08M +37.64% | 2.14M -20.03% | 1.82M -39.10% | 1.79M -12.27% | 2.52M +21.57% | 1.87M -12.43% | 1.63M -10.13% | 1.60M -10.86% | 1.58M -37.50% | 2.25M +20.33% | 1.85M +13.66% | 1.51M -5.63% | 1.55M -1.84% | 2.13M -5.32% | 1.96M +5.71% | 1.99M +31.59% | 7.63M -- |
Selling and Marketing Expenses | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 2.67M -- | -- -- | -- -- | -- -- | 1.14M -57.15% | -- -- | -- -- | -- -- | 518.00K -54.64% | -- -- | -- -- | -- -- | 661.00K +27.61% | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
General and Administrative Expenses | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 5.80M -- | -- -- | -- -- | -- -- | 5.52M -4.79% | -- -- | -- -- | -- -- | 9.26M +67.78% | -- -- | -- -- | -- -- | 7.61M -17.80% | -- -- | 1.63M -- | 1.60M -- | 1.58M -79.28% | 2.25M -- | 1.85M +13.66% | 1.51M -5.63% | 1.55M -1.84% | 2.13M -5.32% | 1.96M +5.71% | 1.99M +31.59% | 7.63M -- |
Research and Development Expenses | 1.53M -- | 2.68M -- | 3.42M -- | 4.70M -- | 6.76M +342.99% | 7.06M +163.85% | 7.00M +104.59% | 8.08M +72.08% | 6.19M -8.48% | 3.95M -44.03% | 3.91M -44.14% | 1.92M -76.26% | 1.76M -71.63% | 1.29M -67.48% | 678.00K -82.67% | 453.00K -76.38% | 469.00K -73.29% | 585.00K -54.51% | 2.18M +221.39% | 2.33M +413.47% | 2.59M +452.24% | 3.29M +462.74% | 2.45M +12.44% | 1.64M -29.49% | 1.09M -57.72% | 460.00K -86.03% | 1.44M -41.10% | 1.69M +2.74% | 2.71M +147.31% | 2.98M +546.96% | 2.19M +52.04% | 1.63M -3.03% | 955.00K -64.73% | 568.00K -80.91% | 462.00K -78.94% | 3.62M -- |
Loss on Impairment of Other Assets | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 5.70M -- | -- -- | -- -- | -- -- | 249.00K -95.63% | -- -- | -- -- | -- -- | 33.91M +13517.67% | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Other Operating Expenses | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 5.29M -- | 0 -- | -5.29M -- | -- -- | -- -- | 249.00K -- | -249.00K +95.29% | 0 -- | 0 -- | -- -- | 0 +100.00% | 1.49M -- | 0 -- | 0 -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- |
Operating Income | -2.16M -- | -3.51M -- | -4.11M -- | -5.71M -- | -7.55M -250.26% | -8.08M -130.43% | -7.85M -90.78% | -10.44M -82.76% | -8.01M -6.02% | -6.25M +22.56% | -6.15M +21.70% | -4.03M +61.38% | -4.12M +48.53% | -8.03M -28.44% | -1.96M +68.04% | -2.30M +42.94% | -3.15M +23.68% | -3.57M +55.60% | -4.47M -127.80% | -4.40M -91.43% | -4.73M -50.40% | -5.11M -43.20% | -4.25M +5.12% | -38.07M -764.71% | -4.45M +5.84% | -2.09M +59.04% | -3.04M +28.32% | -3.26M +91.43% | -4.96M -11.43% | -4.83M -130.93% | -3.70M -21.72% | -3.18M +2.45% | -3.09M +37.74% | -2.53M +47.65% | -2.45M +33.88% | -11.25M -- |
Non-Operating Income (Loss) | 16.18K -- | -97.53K -- | -742.19K -- | -603.52K -- | 1.90M +11671.03% | -9.51M -9652.60% | 4.47M +702.38% | -2.14M -254.95% | -840.00K -144.12% | -14.90M -56.68% | -5.98M -233.69% | 20.65M +1063.77% | -545.00K +35.12% | 1.89M +112.67% | -1.26M +78.99% | -3.35M -116.21% | 27.00K +104.95% | 4.55M +140.89% | 696.00K +155.41% | -149.00K +95.55% | -36.00K -233.33% | 24.00K -99.47% | 82.00K -88.22% | 115.00K +177.18% | 142.00K +494.44% | -1.63M -6879.17% | 444.00K +441.46% | -792.00K -788.70% | 1.62M +1042.25% | 547.00K +133.62% | -1.06M -337.84% | 2.80M +453.66% | -272.00K -116.77% | 1.59M +190.86% | 134.00K +112.69% | 4.25M -- |
Gain (Loss) on Change in Fair Value | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -1.12M -- | -- -- | -- -- | -- -- | -2.43M -117.38% | -- -- | -- -- | -- -- | 5.20M +314.22% | -- -- | -- -- | -- -- | 10.00K -99.81% | -- -- | -1.83M -- | 125.00K -- | -1.03M -10370.00% | 1.40M -- | 362.00K +119.82% | -1.18M -1042.40% | 2.64M +357.06% | -487.00K -134.91% | 1.43M +294.20% | -40.00K +96.60% | 3.54M -- |
Gain (Loss) on Foreign Currency Exchange | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -2.00K -- | -- -- | -- -- | -- -- | -676.00K -33700.00% | -- -- | -- -- | -- -- | -299.00K +55.77% | -- -- | -- -- | -- -- | -72.00K +75.92% | -- -- | -13.00K -- | 3.00K -- | -14.00K +80.56% | -8.00K -- | 13.00K +200.00% | -16.00K -633.33% | -6.00K +57.14% | 10.00K +225.00% | -8.00K -161.54% | 4.00K +125.00% | -- -- |
Other Non-Operating Income (Loss) | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -264.00K -- | -- -- | -- -- | -- -- | 147.00K +155.68% | -36.00K -- | 24.00K -- | 82.00K -- | -69.00K -146.94% | 142.00K +494.44% | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Net Interest Expense | -16.18K -- | 97.53K -- | 742.19K -- | 603.52K -- | -1.90M -11671.03% | 9.51M +9652.60% | -4.47M -702.38% | 2.14M +254.95% | 840.00K +144.12% | 14.90M +56.68% | 5.98M +233.69% | -21.76M -1115.96% | 545.00K -35.12% | -1.89M -112.67% | 1.26M -78.99% | -20.00K +99.91% | -27.00K -104.95% | -4.55M -140.89% | -696.00K -155.41% | 5.19M +26070.00% | -- -- | -- -- | -- -- | -246.00K -104.74% | -- -- | -212.00K -- | -316.00K -- | -249.00K -1.22% | -235.00K -- | -172.00K +18.87% | -138.00K +56.33% | -167.00K +32.93% | -205.00K +12.77% | -172.00K -- | -170.00K -23.19% | -714.00K -- |
Interest Expense | -- -- | 97.53K -- | 742.19K -- | -799.01K -- | -- -- | 9.51M +9652.60% | -- -- | -2.76M -245.58% | 840.00K -- | 14.90M +56.68% | 5.98M -- | -21.43M -676.03% | -- -- | -- -- | 1.26M -78.99% | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Interest Income | 16.18K -- | -- -- | -- -- | -- -- | 1.90M +11671.03% | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 336.00K -- | -- -- | 1.89M -- | -- -- | 20.00K -94.05% | -- -- | 4.55M +140.89% | 696.00K -- | -5.19M -26070.00% | -- -- | -- -- | -- -- | 246.00K +104.74% | -- -- | 212.00K -- | 316.00K -- | 249.00K +1.22% | 235.00K -- | -- -- | 138.00K -56.33% | 167.00K -32.93% | 205.00K -12.77% | -- -- | 170.00K +23.19% | -- -- |
Pretax Income From Continuing Operations | -2.14M -- | -3.60M -- | -4.86M -- | -6.31M -- | -5.65M -163.92% | -17.59M -388.19% | -3.38M +30.43% | -12.58M -99.21% | -8.85M -56.63% | -21.16M -20.29% | -12.12M -258.80% | 16.61M +232.08% | -4.67M +47.25% | -6.15M +70.95% | -3.22M +73.44% | -5.65M -133.98% | -3.12M +33.18% | 981.00K +115.96% | -3.78M -17.33% | -4.55M +19.38% | -4.77M -52.85% | -5.08M -618.25% | -4.16M -10.19% | -37.96M -733.88% | -4.31M +9.53% | -3.72M +26.85% | -2.60M +37.57% | -4.05M +89.32% | -3.34M +22.52% | -4.28M -15.19% | -4.76M -83.15% | -382.00K +90.58% | -3.36M -0.63% | -938.00K +78.10% | -2.31M +51.37% | -7.00M -- |
Income Tax Expense | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | 0 -- | 0 -- | 0 -- | -648.00K -- | -242.00K -- | -155.00K -- | -274.00K -- | -8.87M -1268.98% | -289.00K -19.42% | -446.00K -187.74% | -208.00K +24.09% | -889.00K +89.98% | -724.00K -150.52% | -852.00K -91.03% | -605.00K -190.87% | -1.02M -14.51% | -- -- | 0 +100.00% | 0 +100.00% | -- -- |
Current Income Tax | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 2.00K -- | -- -- | -- -- | -- -- | 3.00K +50.00% | -- -- | -- -- | -- -- | -- -- |
Deferred Income Tax | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -648.00K -- | -- -- | -- -- | -- -- | -9.54M -1372.53% | -- -- | -- -- | -- -- | -1.83M +80.78% | -- -- | -- -- | -- -- | -3.20M -74.59% | -- -- | -- -- | -- -- | -- -- |
Net Income | -2.14M -- | -3.60M -- | -4.86M -- | -6.31M -- | -5.65M -163.92% | -17.59M -388.19% | -3.38M +30.43% | -12.58M -99.21% | -8.85M -56.63% | -21.16M -20.29% | -12.12M -258.80% | 16.61M +232.08% | -4.67M +47.25% | -6.15M +70.95% | -3.22M +73.44% | -5.65M -133.98% | -3.12M +33.18% | 981.00K +115.96% | -3.78M -17.33% | -3.90M +30.85% | -4.52M -45.09% | -4.93M -602.45% | -3.89M -2.94% | -29.09M -645.06% | -4.02M +11.07% | -3.27M +33.60% | -2.39M +38.52% | -3.17M +89.12% | -2.62M +34.95% | -3.43M -4.86% | -4.16M -73.78% | 636.00K +120.09% | -3.36M -28.47% | -938.00K +72.67% | -2.31M +44.28% | -5.98M -- |
Net Income Attributable to Owners of the Company | -2.14M -- | -3.60M -- | -4.86M -- | -6.31M -- | -5.65M -163.92% | -17.59M -388.19% | -3.38M +30.43% | -12.58M -99.21% | -8.85M -56.63% | -21.16M -20.29% | -12.12M -258.80% | 16.61M +232.08% | -4.67M +47.25% | -6.15M +70.95% | -3.22M +73.44% | -5.65M -133.98% | -3.12M +33.18% | 981.00K +115.96% | -3.78M -17.33% | -3.90M +30.85% | -4.52M -45.09% | -4.93M -602.45% | -3.89M -2.94% | -29.09M -645.06% | -4.02M +11.07% | -3.27M +33.60% | -2.39M +38.52% | -3.17M +89.12% | -2.62M +34.95% | -3.43M -4.86% | -4.16M -73.78% | 636.00K +120.09% | -3.36M -28.47% | -938.00K +72.67% | -2.31M +44.28% | -5.98M -- |
Net Income Attributable to Common Stockholders | -2.14M -- | -3.60M -- | -4.86M -- | -6.31M -- | -5.65M -163.92% | -17.59M -388.19% | -3.38M +30.43% | -12.58M -99.21% | -8.85M -56.63% | -21.16M -20.29% | -12.12M -258.80% | 16.61M +232.08% | -4.67M +47.25% | -6.15M +70.95% | -3.22M +73.44% | -5.65M -133.98% | -3.12M +33.18% | 981.00K +115.96% | -3.78M -17.33% | -3.90M +30.85% | -4.52M -45.09% | -4.93M -602.45% | -3.89M -2.94% | -29.09M -645.06% | -4.02M +11.07% | -3.27M +33.60% | -2.39M +38.52% | -3.17M +89.12% | -2.62M +34.95% | -3.43M -4.86% | -4.16M -73.78% | 636.00K +120.09% | -3.36M -28.47% | -938.00K +72.67% | -2.31M +44.28% | -5.98M -- |
Other Comprehensive Income | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Total Comprehensive Income | -2.14M -- | -3.60M -- | -4.86M -- | -6.31M -- | -5.65M -163.92% | -17.59M -388.19% | -3.38M +30.43% | -12.58M -99.21% | -8.85M -56.63% | -21.16M -20.29% | -12.12M -258.80% | 16.61M +232.08% | -4.67M +47.25% | -6.15M +70.95% | -3.22M +73.44% | -5.65M -133.98% | -3.12M +33.18% | 981.00K +115.96% | -3.78M -17.33% | -3.90M +30.85% | -4.52M -45.09% | -4.93M -602.45% | -3.89M -2.94% | -29.09M -645.06% | -4.02M +11.07% | -3.27M +33.60% | -2.39M +38.52% | -3.17M +89.12% | -2.62M +34.95% | -3.43M -4.86% | -4.16M -73.78% | 636.00K +120.09% | -3.36M -28.47% | -938.00K +72.67% | -2.31M +44.28% | -5.98M -- |
Total Comprehensive Income Attributable to Owners of the Company | -2.14M -- | -3.60M -- | -4.86M -- | -6.31M -- | -5.65M -163.92% | -17.59M -388.19% | -3.38M +30.43% | -12.58M -99.21% | -8.85M -56.63% | -21.16M -20.29% | -12.12M -258.80% | 16.61M +232.08% | -4.67M +47.25% | -6.15M +70.95% | -3.22M +73.44% | -5.65M -133.98% | -3.12M +33.18% | 981.00K +115.96% | -3.78M -17.33% | -3.90M +30.85% | -4.52M -45.09% | -4.93M -602.45% | -3.89M -2.94% | -29.09M -645.06% | -4.02M +11.07% | -3.27M +33.60% | -2.39M +38.52% | -3.17M +89.12% | -2.62M +34.95% | -3.43M -4.86% | -4.16M -73.78% | 636.00K +120.09% | -3.36M -28.47% | -938.00K +72.67% | -2.31M +44.28% | -5.98M -- |
Basic EPS | -0.15 -- | -0.25 -- | -0.32 -- | -0.25 -- | -0.18 -20.00% | -0.48 -92.00% | -0.05 +84.38% | -0.16 +36.00% | -0.11 +38.89% | -0.25 +47.92% | -0.14 -180.00% | 0.18 +212.50% | -0.05 +54.55% | -0.52 -108.00% | -0.26 -85.71% | -0.03 -116.67% | -0.12 -140.00% | 0.03 +105.77% | -0.09 +65.38% | -0.09 -200.00% | -0.61 -408.33% | -0.66 -2300.00% | -0.52 -477.78% | -0.65 -622.22% | -0.54 +11.48% | -0.43 +34.85% | -0.21 +59.62% | -0.34 +47.69% | -0.24 +55.56% | -0.3 +30.23% | -0.36 -71.43% | 0.05 +114.71% | -0.21 +12.50% | -0.06 +80.00% | -0.14 +61.11% | -0.36 -- |
Basic EPS from Continuing Operations | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -0.43 -- | -0.21 -- | -- -- | -0.24 -- | -0.3 +30.23% | -0.36 -71.43% | -- -- | -0.21 +12.50% | -0.06 +80.00% | -0.14 +61.11% | -- -- |
Diluted EPS | -0.15 -- | -0.25 -- | -0.32 -- | -- -- | -0.18 -20.00% | -0.48 -92.00% | -0.05 +84.38% | -- -- | -0.11 +38.89% | -0.25 +47.92% | -0.14 -180.00% | -- -- | -0.05 +54.55% | -0.52 -108.00% | -0.26 -85.71% | -- -- | -0.12 -140.00% | 0.03 +105.77% | -0.09 +65.38% | -- -- | -0.61 -408.33% | -0.66 -2300.00% | -0.52 -477.78% | -- -- | -0.54 +11.48% | -0.43 +34.85% | -0.21 +59.62% | -- -- | -0.24 +55.56% | -0.3 +30.23% | -0.36 -71.43% | -- -- | -0.21 +12.50% | -0.06 +80.00% | -0.14 +61.11% | -- -- |
Diluted EPS from Continuing Operations | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -0.43 -- | -0.21 -- | -- -- | -0.24 -- | -0.3 +30.23% | -0.36 -71.43% | -- -- | -0.21 +12.50% | -0.06 +80.00% | -0.14 +61.11% | -- -- |
You can ask Aime
What is Grace Therapeutics's gross profit margin?What is Grace Therapeutics's latest dividend and current dividend yield?What were the key takeaways from Grace Therapeutics's earnings call?What is the market's earnings forecast for Grace Therapeutics next quarter?What were the key takeaways from Grace Therapeutics’s earnings call?What is the revenue and EPS growth rate for Grace Therapeutics year over year?What guidance did Grace Therapeutics's management provide for the next earnings period?What factors drove the changes in Grace Therapeutics's revenue and profit?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
